Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for MNTA
10.77
-0.16 (-1.46%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.75 - 11.09
52 week 9.38 - 18.97
Open 10.89
Vol / Avg. 540,008.00/666,174.00
Mkt cap 571.36M
P/E     -
Div/yield     -
EPS -2.19
Shares 53.05M
Beta 1.95
Inst. own 84%
Feb 25, 2015
Momenta Pharmaceuticals Inc at RBC Healthcare Conference - 8:00AM EST - Add to calendar
Feb 11, 2015
Momenta Pharmaceuticals Inc at Leerink Global Healthcare Conference - 1:25PM EST - Add to calendar
Feb 9, 2015
Q4 2014 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 1, 2014
Momenta Pharmaceuticals Inc at Deutsche Bank BioFEST
Nov 20, 2014
Momenta Pharmaceuticals Inc at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 19, 2014
Momenta Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 12, 2014
Momenta Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 5, 2014
Q3 2014 Momenta Pharmaceuticals Inc Earnings Call - Webcast
Nov 5, 2014
Q3 2014 Momenta Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -311.71% -305.68%
Operating margin -313.57% -309.01%
EBITD margin - -285.89%
Return on average assets -45.84% -29.97%
Return on average equity -54.84% -34.40%
Employees 269 -
CDP Score - -

Address

675 West Kendall Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Momenta Pharmaceuticals, Inc. is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel Drugs. The Company�s approach is built around a complex systems analysis platform that it uses to obtain a detailed understanding of complex chemical and biologic systems, design product candidates, analyze sets of biological data to evaluate the biological function of its products and develop manufacturing processes that enable its products to be reliably produced. The Company uses its complex systems analysis platform to define the detailed structures present in these complex drugs. To demonstrate that the biological function of the Company�s generic replicates that of the brand, the Company utilizes its complex systems analysis platform to evaluate and compare multiple orthogonal sets of biologic data from in-vitro, in-vivo and ex-vivo models.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 62
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Bruce A. Leicher Esq. Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 52
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 61
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 66
Bio & Compensation  - Reuters